NCT01608087View on ClinicalTrials.gov

Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

May 1, 2012

Primary Completion Date

November 1, 2012

Study Completion Date

November 1, 2012

Conditions
Healthy
Interventions
DRUG

BI 695502

BI 695502 single i.v. infusion

DRUG

bevacizumab

bevacizumab single i.v. infusion

DRUG

bevacizumab

bevacizumab single i.v. infusion

Trial Locations (2)

Unknown

1302.1.002 Boehringer Ingelheim Investigational Site, Auckland NZ

1302.1.001 Boehringer Ingelheim Investigational Site, Christchurch

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY